California's Stem Cell and Gene Therapy Agency Troubled by Morale Problems, Pay Inequality and More, Says Audit
CIRM also was a laggard in work on three-year-old audit recommendations
The $12 billion California stem cell agency is suffering from a wide array of afflictions, ranging from employee morale problems and an excessively large governing board to pay inequity and royalty income issues, according to the agency’s latest performance audit.
The big changes included in a ballot initiative that saved the agency from financial extinction in 2020 “made it difficult for employees to keep up,” the audit said. Tensions involving work-at-home standards troubled staff members. The agency’s president was burdened with too many persons (11) reporting directly to her, the audit declared.
The findings of the study, required by state law every three years, shed light on the abrupt resignation of Maria T. Millan as its president and CEO in November.
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.